The outcome of intralesional vitamin D3 (alphacalcidol) injection in treatment of cutaneous warts
DOI:
https://doi.org/10.66344/jpad.v33i4.2344Keywords:
Intralesional, Vitamin D3, Human papillomavirus (HPV), Cutaneous wartsAbstract
Objective The objective of this study was to see the efficacy of intralesional vitamin D3 injection in treatment of warts. The efficacy was assessed in the term of ≥50% improvement in warts after treatment at 3rd month.
Methods This was a descriptive case series study and was completed in 6 months duration in dermatology department, Mayo hospital Lahore. A total of 97 cases of cutaneous warts fulfilling inclusion criteria were enrolled after getting approval from hospital ethical committee. All cases were included through OPD of Dermatology, Mayo Hospital Lahore after taking informed consent. Initially, lesions were anaesthetized with 0.1 ml of prilocaine (20 mg/ml). A 21-gauge syringe was used to inject 0.2 ml of vitamin D3 (7.5 mg/ml) slowly into the base of each wart. According to the treatment protocol, injections of vitamin D3 were given monthly with a maximum of 2 sessions. Per single session, the total amount injected into a patient was 7.5 mg. The whole procedure was done by consultant dermatologist having more than 5 years of experience. The treatment response ≥ 50% was recorded as per operational definition at 3rd month. All data was recorded by researchers themselves on the prescribed proforma.
Results The mean age of all cases was 40.94±11.53 with minimum and maximum age as 18 and 60 years. There were 56 (57.7%) male and 41 (42.3%) female cases. A total of 79 (81.4%) cases achieved efficacy of treatment while in 18 (18.6%) cases efficacy was not seen. Efficacy was seen in 77.5% cases who had duration of disease < 6 months and 92.3% of cases who had duration of disease since ≥ 6 months. The frequency of efficacy was statistically same in both genders and both duration of disease groups. These results showed that intralesional vitamin D3 was effective in the treatment of different types of cutaneous warts with high significance level.
Conclusion It was concluded that intralesional vitamin D3 injection was highly effective in treatment of cutaneous warts. Hence, intralesional vitamin D3 being an effective, inexpensive and safe treatment must be opted for this common problem in our society.
References
1. Aldahan AS, Mlacker S, Shah VV, Kamath P, et al. Efficacy of intralesional immunotherapy for the treatment of warts: A review of the literature. Dermatol Ther.2016;29(3):197-207.
2. Kumar N, Warren CB. Photodynamic therapy for dermatologic conditions in the pediatric population: a literature review. Photodermatol Photoimmunol Photomed. 2017;33(3):125-34.
3. Khozeimeh F, Azad FJ, Oskouei YM, Jafari M, et al. Intralesional immunotherapy comparedto cryotherapy in the treatment of warts. Int J Dermatol. 2017;56(4):474-8.
4. López GS, Domínguez LM, Leyva JR, et al. General aspects of structure, classification and replication ofhuman papillomavirus. Rev Médica Inst Mex Seguro Soc. 2015;53:166-171.
5. Yousefi Z, Aria H, Ghaedrahmati F, et al. An update on human papilloma virus vaccines: history, types, protection, and efficacy. Front. Immunol.2022;12:1-11
6. Handler NS, Handler MZ, Majewski S, Schwartz RA. Humanpapilloma virus vaccine trialsand tribulations: vaccine efficacy. J Am Acad Dermatol. 2015;73(5):759-67.
7. Singh S, Chouhan K, Gupta S. Intralesional immunotherapy with killed Mycobacterium indicus pranii vaccine for the treatment of extensive cutaneous warts. Indian J Dermatol Venereol Leprol.2014;80(6):509-14.
8. Ghadgepatil SS, Gupta S, Sharma YK. Clinioepidemiological study of different types of warts. Dermatol Res Pract.2016:1-4
9. Witchey DJ, Witchey NB, Roth-Kauffman MM, Kauffman MK. Plantar Warts: Epidemiology, Pathophysiology, and Clinical Management. Osteopath Med.2018;118(2): 92-105.
10. Hussain F, Ormerod A. Nongenital warts: clinical features and recommended treatment. Prescriber. 2009;20(22):20-6.
11. Nofal A, Nofal E, Yosef A, Nofal H. Treatment of recalcitrant warts with intralesional measles, mumps, and rubella vaccine: a promising approach. Int J Dermatol. 2015;54(6):667-71.
12. Nofal A, Yosef A, Salah E. Treatment of recalcitrant warts with Bacillus Calmette-Guerin: a promising new approach. Dermatol Ther.2013;26(6):481-5.
13. Aktas H, Ergin C, Demir B, Ekiz O. Intralesional Vitamin D Injection May Be an Effective Treatment Option for Warts. J Cutan Med Surg.2016;20(2):118-22.
14. Raghukumar S, Ravikumar BC, Vinay KN, Suresh MR, Aggarwal A, et al. Intralesional Vitamin D3 Injection in the Treatment of recalcitrant Warts: A Novel Proposition. J Cutan Med Surg. 2017;21(4):320-4.
15. Rivera A, Tyring SK. Therapy of cutaneous human papilloma virus infections. Dermatol Ther. 2004;17(6):441-8.
16. Bacelieri R, Johnson SM. Cutaneous warts: an evidence-based approach to therapy. Am Fam Physician. 2005;72(4):647-52.
17. Nofal A, Salah E, Nofal E, Yosef A. Intralesional antigenimmuno therapy for the treatment of warts: current concepts and future prospects. Am J Clin Dermatol. 2013;14(4):253-60.
18. Kavya M, Shashikumar BM, Harish MR, Shweta BP. Safety and efficacy of intralesional vitamin D3 in cutaneous warts: An open uncontrolled trial. J Cutan Aesthet Surg. 2017;10(2):90-4.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Asma Masood, Noshi Ilyas, Saira Riaz, Nehel Raza, Burhan Ashraf, Sara Mubeen, Muhammad Khalil-ur-Rehman, Shahbaz Aman, Tahir Jamil
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
